DarioHealth Corp.

Thank you. ... ... Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you.

Good morning, ladies and gentlemen, and welcome to the Dario Health Fourth Quarter and Near End 2025 Results Conference Call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question and answer session. If at any time during this call you require immediate assistance, please press star zero for the operator. This call is being recorded on Thursday, March 19, 2026. I would now like to turn the conference over to Zoe Harrison, VP Accounting and Corporate Development at Dario Health. Zoe, please go ahead.

Thank you, operator, and good morning, everyone. Thank you for joining us today for a discussion of Dario Health's fourth quarter and GAN 2025 financial results. Leading the call today will be Erez Rafael, chief executive officer of Dario Health. He'll be joined by our president and chief commercial officer, Steven Nelson, and Hen Franker, our chief financial officer. An audio recording and webcast replay for today's call will also be available online as detailed in the press release invite for this call. For the benefit of those who may be listening to the replay or archived webcast, this call is being held on Thursday, March 19, 2026. This morning, we issued a press release announcing our financial results for the fourth quarter and year end 2025. The copy of the release can be found on the investor relations page of Dario Health website. I'd like to remind you that on this call, we will make forward-looking statements within the meaning of the federal securities laws. For example, the company is using forward-looking statements when it is discussing statements regarding the expected timing and contribution of agreement signed in 2025 to revenue in 2026 and 2027, anticipated revenue growth trends, and the timing of acceleration during 2026, the size, composition, and potential conversion of the company's commercial pipeline. expected onboarding, enrollment ramp, and expansion of employer health plan and channel partner relationships. The anticipated benefits of the company's multi-condition platform, AI capabilities, Dario IQ, expectations regarding the future operating efficiencies, margins, and operating expense reductions. The company's expectation that it may reduce the operating loss by 30% in 2026, reach cash flow break-even by mid-2027, and future strategic opportunities, including a sale, merger, strategic business combination, or continued execution of the company's standalone strategy. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond the company's control, including the risks described from time to time in its SEC filings. The company's results may differ materially from those projections. These statements involve material risks and uncertainties that could cause actual results or events to materially differ. Accordingly, you should not place undue reliance on these statements. I encourage you to review the company's filings with the SEC, including without limitation, the company's annual report on Form 10-K, which identifies specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements. With that, I'll hand it over to Erez Rafael, Chief Executive Officer of Dario Health.